



MATERIAL SAFETY DATA SHEET

SECTION 1 - IDENTIFICATION OF PRODUCT AND COMPANY

Pfizer Inc	Emergency telephone	1-866-531-8896
Pfizer Animal Health	Hours of operation	24 Hours
235 East 42nd Street	Telephone	1-800-366-5288
New York, NY 10017		

Trade names	ALBON® SUSPENSION 5%
Product name	ALBON® (sulfadimethoxine) SUSPENSION 5%
Synonyms	Sulfadimethoxine Suspension 5%
Chemical family	Sulfonamide
Therapeutic use	Antibiotic agent
Description	Smooth, uniform yellow suspension with a sweet odor

SECTION 2 - COMPOSITION

<u>Ingredient</u>	<u>CAS Number</u>	<u>Amount</u>
Sulfadimethoxine*	122-11-2	5.0%
Carbomer	9003-01-4	Proprietary
Citric acid monohydrate*	5949-29-1	Proprietary
FD & C Yellow No. 5	1934-21-0	Proprietary
FD&C yellow No. 6	2783-94-0	Proprietary
Invert sugar	8013-17-0	Proprietary
Flavor	Not assigned	Proprietary
Methylcellulose	9004-67-5	Proprietary
Pluronic F-68	9003-11-6	Proprietary
Sodium benzoate	532-32-1	Proprietary
Sodium citrate, dihydrate*	6132-04-3	Proprietary
Sodium hydroxide NF*	1310-73-2	Proprietary
Sucrose*	57-50-1	Proprietary

*Hazardous

Note: Ingredient(s) indicated as hazardous have been assessed under US OSHA Hazard Communication Standard for workplace safety (29 CFR 1910.1200).

SECTION 3 - HAZARDS IDENTIFICATION

Signal word	CAUTION!
Statements of hazard	MAY CAUSE ALLERGIC REACTION IN INDIVIDUALS SENSITIVE TO SULFONAMIDES.

SECTION 3 - HAZARDS IDENTIFICATION ... continued

Eye effects	None known
Skin effects	Contact with sulfonamides may cause dermatitis. Allergic skin reaction may occur based on effects of other sulfonamides.
Inhalation effects	An Occupational Exposure Limit has been established for one or more of the ingredients (see Section 8). See 'Statements of hazard' and/or 'Other potential health effects' in this section.
Ingestion effects	Accidental ingestion may cause effects similar to those seen in clinical use. See 'Statements of hazard' and/or 'Other potential health effects' in this section.
Other potential health effects	Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. As in all sulfonamide therapy, the following reactions may occur including nausea, vomiting, diarrhea, inflammation of the liver and pancreas, blood disorder, drug fever, skin rash, infection of the conjunctiva and sclera, blood in the urine and crystalluria.
NOTE:	This document has been prepared in accordance with the US OSHA Hazard Communication Standard, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace. If your workplace is regulated by OSHA, this document must be used as a part of a complete hazard-training program.

SECTION 4 - FIRST AID MEASURES

Skin	Remove contaminated clothing and shoes. Wash skin with soap and water. Wash clothing and thoroughly clean shoes before reuse. If irritation occurs or persists, get medical attention.
Eyes	Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.
Inhalation	Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.
Ingestion	Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

SECTION 5 - FIRE FIGHTING MEASURES

Fire fighting instructions	Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Evacuate area and fight fire from a safe distance.
-----------------------------------	---

SECTION 5 - FIRE FIGHTING MEASURES ... continued

Extinguishing media	Water, dry powder or foam extinguishers are recommended.
Flash point	No data available
Hazardous combustion products	Not known

SECTION 6 - ACCIDENTAL RELEASE MEASURES

General	Review Sections 3, 8 and 12 before proceeding with clean up.
Small spill	Use non-combustible absorbent material to wipe up spill and place in a sealed container for disposal. Clean spill area thoroughly.
Large spill	Dike, pump, or use non-combustible material to absorb spill; then place in a suitable, labeled recovery container. Close container and move it to a secure holding area.

SECTION 7 - HANDLING AND STORAGE

General handling	Use only in a well-ventilated area. Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing.
Storage conditions	Store in a cool, dry place.
Temperature range for storage	Store as directed by product packaging.

SECTION 8 - EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure limits			
<u>Compound</u>	<u>Issuer</u>	<u>Type</u>	<u>OEL</u>
Sucrose	OSHA	TWA-8 Hr	5 mg/m ³ (respirable fraction)
	OSHA	TWA-8 Hr	15 mg/m ³ (total dust)
	ACGIH	TWA-8 Hr	10 mg/m ³
Exposure information	The exposure limit(s) listed for solid components are only relevant if dust may be generated.		
Ventilation	General room ventilation is adequate unless the process generates dust, mist or fumes.		
Respiratory protection	Respiratory protection is not expected to be necessary under normal handling conditions; required only if mist is generated.		
Eye protection	Wear safety glasses with sideshields if eye contact is possible.		
Skin protection	Wear protective clothing with long sleeves to avoid skin contact. Wash hands and arms thoroughly after handling this mixture.		

SECTION 8 - EXPOSURE CONTROLS/PERSONAL PROTECTION ... continued

Hand protection Wear protective gloves to avoid routine skin contact.

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical form Smooth, uniform suspension
Color Yellow
Odor Sweet
Molecular weight Mixture
Molecular formula Mixture
pH 4.4-4.8
Boiling point No data available
Melting point Not applicable
Density No data available
Vapor pressure No data available
Water solubility No data available
Solvent solubility No data available
Specific gravity 1.26-1.28 @ 25°C

SECTION 10 - STABILITY AND REACTIVITY

Reactivity Stable
Conditions to avoid Direct sunlight, conditions that might generate heat and dispersion as a dust cloud
Incompatibilities Strong oxidizers
Hazardous decomposition products No data available
Hazardous polymerization Will not occur

SECTION 11 - TOXICOLOGY INFORMATION

Toxicology summary There are no data for this formulation. The information included in this section describes the potential hazards of the active ingredient, except where noted.

SECTION 11 - TOXICOLOGY INFORMATION ... continued

Acute toxicity

<u>Compound</u>	<u>Type</u>	<u>Route</u>	<u>Species</u>	<u>Dosage</u>
Sulfadimethoxine	LD ₅₀	Oral	Rat	>10 g/kg
Sodium benzoate	LD ₅₀	Oral	Mouse	1600 mg/kg

Eye No data available

Skin Dermatitis may occur from contact of sulfonamides with the skin.

Inhalation No data available

Ingestion See Acute toxicity table

Mutagenicity Other sulfonamide drugs which have been evaluated are not mutagenic.

Sensitization Hypersensitivity reactions to sulfonamides have been reported.

Subchronic effects In rats, oral dosing of 9,100 mg/kg sulfadimethoxine for 13 weeks caused changes in thyroid weight (goitrogenic effect) and decreased weight gain. Sulfonamides are known to be goitrogenic, but not in primates or humans. Dogs given daily oral doses of 160 mg/kg sulfadimethoxine for 13 weeks showed no signs of toxicity.

**Chronic effects/
carcinogenicity** Studies to evaluate the carcinogenic potential of sulfadimethoxine were not available. Other sulfonamide drugs which have been evaluated are not carcinogenic.

Carcinogen status None of the components of this formulation is listed as a carcinogen by IARC, NTP or OSHA.

Reproductive effects Not determined

Teratogenicity In humans, sulfonamides administered prior to delivery can cause jaundice and hemolytic anemia in the offspring. Studies in pregnant laboratory animals administered sulfadimethoxine have shown developmental effects, but retrospective studies in humans with other sulfonamides have not been conclusive.

**At increased risk from
exposure** Like other sulfonamides, this material might produce hypersensitivity reactions in some individuals.

SECTION 12 - ECOLOGICAL INFORMATION

Environmental overview The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

SECTION 13 - DISPOSAL INFORMATION

Disposal procedure Incineration is the recommended method of disposal for this material. Observe all local and national regulations when disposing of this material.

SECTION 14 - TRANSPORTATION INFORMATION

General shipping instructions	Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
--------------------------------------	--

SECTION 15 - REGULATORY INFORMATION

EU Classification	Irritant
--------------------------	----------

EU Labelling	Xi
---------------------	-----------

EU Label Pictogram(s)	
------------------------------	--



Risk phrases	R43 - May cause sensitization by skin contact.
---------------------	--

Safety phrases	S37 - Wear suitable gloves.
-----------------------	-----------------------------

TSCA status	Not listed
--------------------	------------

SARA section 302	No
-------------------------	----

SARA section 313	No
-------------------------	----

California Proposition 65	Not listed
----------------------------------	------------

Canadian WHMIS	Class D, Division 2, Subdivision B
-----------------------	------------------------------------

SECTION 16 - OTHER

Disclaimer	Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.
-------------------	---